Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02145143
Other study ID # 14-031
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date May 2014
Est. completion date May 2025

Study information

Verified date June 2024
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to find out what effects, good and/or bad, a drug called vemurafenib, either alone or combined with another treatment called radioactive iodine, has on the patient and thyroid cancer. It is not known if vemurafenib works against thyroid cancer. This study will test in a small number of patients if it can be used with radioactive iodine to treat thyroid cancers. This type of study is called a pilot study. If the results are positive, a larger study with more patients may be done to further test this treatment.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date May 2025
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary, follicular, or poorly differentiated subtypes and their respective variants). - Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600. - Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as = 20 mm with conventional techniques or as = 10 mm with CT scan, MRI, or calipers by clinical exam. See Section 11 for the evaluation of measurable disease. Tumors in previously irradiated fields may be considered measureable if there is evidence of tumor progression after radiation treatment. - RAI-refractory disease on structural imaging, defined as any one of the following: 1. A metastatic lesion that is not radioiodine-avid on a diagnostic radioiodine scan performed up to 2 years prior to enrollment in the current study, or 2. A radioiodine-avid metastatic lesion which remained stable in size or progressed despite radioiodine treatment 6 months or more prior to entry in the study. There are no size limitations for the index lesion used to satisfy this entry criterion. 3. The presence of at least one fluorodeoxyglucose (FDG) avid lesion with a SUVmax = 5. - No recent treatment for thyroid cancer as defined as: 1. No prior 131I therapy is allowed < 6 months prior to initiation of therapy on this protocol. A diagnostic study using < 10 mCi of 131I is not considered 131I therapy. 2. No external beam radiation therapy < 4 weeks prior to initiation of therapy on this protocol. (Previous treatment with radiation for any indication is allowed if the investigator judges that the previous radiation does not significantly compromise patient safety on this protocol.) 3. No chemotherapy or targeted therapy (e.g., tyrosine kinase inhibitor) is allowed < 4 weeks prior to the initiation of therapy on this protocol. - Age = 18 years. - ECOG performance status = 2 (or Karnofsky =60% - Life expectancy of greater than 3 months. - Able to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels. - All prior treatment-related toxicities must be CTCAE v4.0 grade = 1 (except alopecia). Grade 2 prior treatment related toxicities may be allowed after discussion with the Principal Investigator. - Patients must have normal organ and marrow function as defined below: - Absolute neutrophil count (ANC) = 1.5x109/L - Hemoglobin = 9 g/dL - Platelets = 100 x 109/L - Albumin = 2.5 g/dL - Total bilirubin = 1.5x institutional ULN - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2x institutional ULN unless it is related to the primary disease - Creatinine = 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault formula) = 50 mL/min OR 24-hour urine creatinine clearance = 50 mL/min - Negative pregnancy test within 7 days prior to starting the study premenopausal women. Women of non-childbearing potential may be included without pregnancy test if they are either surgically sterile or have been postmenopausal for = 1 year. - Fertile men and women must use an effective method of contraception during treatment and for at least 6 months after completion of treatment as directed by their physician. Effective methods of contraception are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices). At the discretion of the Investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.) - Ability to understand and the willingness to sign a written informed consent document. - Patients must agree to undergo two research biopsies of a malignant lesion. Patients may be exempt from biopsy if 1) the investigator or person performing the biopsy judges that no tumor is accessible for biopsy, 2) the investigator or person performing the biopsy feels that the biopsy poses too great of a risk to the patient, or 3) the patient's platelet count is <100,000/mcl or he/she can not be safely removed from anti-coagulation therapy (if the anti-coagulation therapy needs to be temporarily held for the biopsy procedure). If the only tumor accessible for biopsy is also the only lesion that can be used for RECIST v1.1 response evaluation, then the patient may be exempt from biopsy. The goal will be to have a minimum of 3 patients undergo one or both of these research biopsies. Accrual may be limited only to subjects whose tumor is safely accessible for biopsy to ensure the accrual goal for research biopsies described above is met (e.g., if 7 of 10 patients are accrued without any biopsies having been obtained, then all subsequent subjects who are registered must qualify for attempted research biopsy in order to be enrolled.) - Availability of archival tumor tissue from the thyroid cancer primary or metastasis (a tissue block or a minimum of 30 unstained slides would be required. Patients with less archival tissue available may still be eligible for the study after discussion with the MSK Principal Investigator.) Exclusion Criteria: - Concomitant malignancies or previous malignancies within the last 3 years. Exception: Patients who have been disease-free for 3 years, patients with a history of completely resected non-melanoma skin cancer, and/or patients with indolent secondary malignancies, are eligible. - Use of other investigational drugs within 28 days preceding the first dose of vemurafenib during this study. - Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. - Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to vemurafenib or thyrotropin alpha (Thyrogen). - History or evidence of cardiovascular risk including any of the following: - Corrected QT (QTc) interval = 450 msec at baseline or history of congenital long QT syndrome or uncorrectable electrolyte abnormalities - History or evidence of current, clinically significant uncontrolled arrhythmias (exception: patients with controlled atrial fibrillation for > 30 days prior to the initiation of therapy on this protocol are eligible). - History of acute coronary syndromes (specifically, myocardial infarction and unstable angina), severe/unstable angina, coronary angioplasty, or stenting within 6 months prior to the initiation of therapy on this protocol. - History of symptomatic congestive heart failure within 6 months prior to the initiation of therapy on this protocol. - History of cerebrovascular attack or transient ischemic attack within 6 months prior to the initiation of therapy on this protocol. - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements. - Pregnant, lactating, or breast feeding women. - Patients unable to follow a low iodine diet or requiring medication with high content in iodide (amiodarone). - Patients who received iodinated intravenous contrast as part of a radiographic procedure within 3 months of study registration. Those that have had iodinated intravenous contrast within this time frame may still be eligible if a urinary iodine analysis reveals that the excess iodine has been adequately cleared after the last intravenous contrast administration. - Unwillingness or inability to comply with study and follow-up procedures.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vemurafenib

Device:
serial 124I PET/CT

Drug:
thyrotropin alpha


Locations

Country Name City State
United States Memorial Sloan Kettering Cancer Center New York New York

Sponsors (2)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The duration of overall CR is measured from the time measurement criteria are first met for CR until the first date that progressive disease is objectively documented. 1 year
Secondary objective response rate (ORR) To evaluate the effect of vemurafenib on enhancing 131I activity by determining the ORR by RECIST v1.1 criteria at 6 months following treatment with vemurafenib +/- 131I. 6 months
Secondary safety Toxicities will be assessed through the NCI-Common Terminology Criteria for Adverse Events version 4.0, individually reported and summarized. Monitoring for vemurafenib-related toxicities will be continued until 30 days after the last dose of drug therapy. 1 year
See also
  Status Clinical Trial Phase
Completed NCT02658513 - Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
Withdrawn NCT01707056 - The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma N/A
Completed NCT00215605 - Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies Phase 1
Completed NCT06439745 - More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
Terminated NCT04327999 - Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System Phase 2
Completed NCT02194920 - Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function N/A
Enrolling by invitation NCT06095362 - Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW Phase 1
Not yet recruiting NCT05949424 - OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults Phase 4
Terminated NCT01865838 - A Study Into the Effect of Seprafilm in Open Total Thyroidectomy N/A
Recruiting NCT00749697 - Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases N/A
Enrolling by invitation NCT04411290 - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Completed NCT01813136 - Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Phase 2
Recruiting NCT05668962 - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Phase 2
Active, not recruiting NCT02185560 - Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Completed NCT04462471 - Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Phase 1
Completed NCT01433809 - Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm N/A
Recruiting NCT00929318 - Influence of Thyroid Hormones on the Woundhealing Process N/A
Completed NCT05178186 - Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer N/A
Completed NCT02773667 - Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine
Not yet recruiting NCT00993837 - Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma N/A